BioSpace News Archive

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announces today its financial results for the fourth quarter

—HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th— —Roth Conference at 10:00 am ET on March 15 th — —Oppenheimer Healthcare Conference at 1:50 pm ET on March 17 th —

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences:

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and Treasurer effective February 1, 2021.

Biosero, Inc. and Celltrio, Inc. will integrate Biosero’s Green Button Go™ Automation Scheduling Software with Celltrio’s innovative RoboCell™ Automation Platform to accelerate cell line culturing and harvesting processes, including cryogenic storage, into a highly flexible and modular end-to-end system.

Baring Private Equity Asia retains ownership of fast-growing Aesthetics and Vision businesses, to reinvest part of deal proceeds to accelerate growth

Devastated by the loss of her husband Kenneth Bruntel to pancreatic cancer, Gail Coleman is laser-focused on funding research offering hope and better treatment options for patients with metastatic cancer.

Ridgeback Biotherapeutics, LP today announced the publication of results from its first-in-human Phase 1 study of molnupiravir (EIDD-2801/MK-4482) in healthy volunteers.

BioNJ, the life sciences trade association for New Jersey, has released the agenda and speaker roster for its Inaugural Diversity, Equity & Inclusion..Because It Matters Conference, taking place virtually on March 24 and 25, 2021.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided corporate highlights.